
To assess composite endpoints combining glycemic control (HbA1c <7.0%, ≤6.5%, or <5.7%) with weight loss (≥5%, ≥10%, or ≥15%) and without hypoglycemia with tirzepatide in type 2 diabetes (T2D). Data from the phase 3 SURPASS program were evaluated post hoc by trial. The proportions of participants achieving the composite endpoints were compared between tirzepatide and the respective comparator groups at week 40/52. Across the SURPASS‐1 to ‐5 clinical trials, more tirzepatide‐treated participants with T2D achieved clinically meaningful composite endpoints, which included reaching glycemic targets with various degrees of weight loss and without hypoglycemia, than those in the comparator groups.
Like
Save
Share